Xtandi Approved for Metastatic Castration-Resistant Prostate Cancer

Share this content:
Xtandi (enzalutamide) approved for the treatment of patients with metastatic castration-resistant prostate cancer.
Xtandi (enzalutamide) approved for the treatment of patients with metastatic castration-resistant prostate cancer.

Astellas and Medivation announced that the Food and Drug Administration has approved a new indication for Xtandi (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

Xtandi is an oral androgen receptor inhibitor already approved for patients with metastatic CRPC who have previously received docetaxel. This new approval is based on priority review of the supplemental New Drug Application (sNDA) comprised of results from the Phase 3 PREVAIL trial.

RELATED: Enzalutamide (Xtandi®) Improves Quality of Life in Patients With Metastatic Castration-Resistant Prostate Cancer

Results of the PREVAIL trial showed that men receiving Xtandi and GnRH therapy exhibited a statistically significant improvement in both overall survival an delayed time to radiographic progression (83%, HR=0.17; P<0.0001) or death (29%, HR=0.71; P<0.0001) as compared to those on placebo and GnRH therapy. Xtandi also delayed time to initiation of chemotherapy and time to a skeletal related event.

Xtandi is available in 40mg strength capsules in 120-count bottles.

For more information call (800) 695-4321 or visit Xtandi.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs